search
Back to results

Energy -Sensing Metabolites in Caloric Restriction

Primary Purpose

Obesity, Insulin Sensitivity/Resistance, Diabetes Type 2

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
dietary intervention
Sponsored by
Institut Investigacio Sanitaria Pere Virgili
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring obesity, diabetes, intermittent fasting, energy-sensing metabolites

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • White men and women between 18 and 65 years of age.
  • BMI range between 25 and 40 kg/m2
  • Absence of underlying pathology in medical and physical examination, except for those related to excess weight.
  • Signature of the informed consent for participation in the study.

Exclusion Criteria:

  • Serious systemic disease not related to obesity, such as cancer, kidney or severe liver disease.
  • Systemic diseases with intrinsic inflammatory activity (autoimmune diseases such as rheumatoid arthritis and asthma)
  • Pregnancy and lactation.
  • Vegetarians or subjects subjected to an irregular diet.
  • Patients with severe eating disorders.
  • Patients with clinical symptoms and signs of infection in the previous month.
  • Patients with chronic anti-inflammatory steroid treatments and/or nonsteroidal anti-inflammatory drugs.
  • Recent antibiotic treatment.
  • Psychiatric history.
  • Uncontrolled alcoholism or drug abuse.

Sites / Locations

  • Hospital Universitari Joan XXIII de Tarragona. IISPV

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

conventional caloric restriction diet

Intermitent fasting

Arm Description

(DCR protocol): lifestyle recommendations for a healthy Mediterranean diet under a continued daily caloric restriction diet

Fasting for two days (non-consecutive) out of seven, with the fasting days separated by at least one day.

Outcomes

Primary Outcome Measures

To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of glucose)
Plasma concentrations of glucose during a meal test
To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of insulin)
Plasma concentrations of insulin during a meal test
To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of glucose after crossing arm)
Plasma concentrations of glucose during a meal test
To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of insulin after crossing arm)
Plasma concentrations of insulin during a meal test

Secondary Outcome Measures

1) the dynamics of gastrointestinal hormones and energy sensing metabolites
GLP-1; GLP-2 during a meal test
2) Analysis of microbial species in fecal samples (gut flora)
intestinal microbiome after each interventional period
variability on succinate after weight loss
quantification of succinate
variability on Short-chain fatty acids (SCFAs) after weight loss
quantification of SCFAs
variability on Medium-chain fatty acids (MCFAs) after weight loss
quantification of MACFAs
variability on biliary acids (BA) after weight loss
quantification of BA

Full Information

First Posted
August 20, 2021
Last Updated
October 9, 2022
Sponsor
Institut Investigacio Sanitaria Pere Virgili
search

1. Study Identification

Unique Protocol Identification Number
NCT05031572
Brief Title
Energy -Sensing Metabolites in Caloric Restriction
Official Title
New Energy-sensing Metabolites: Beneficial Effects on Metabolic Health in Obesity Comparing Diary Caloric Restriction vs Intermittent Fasting. A Randomized Cross-over Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
August 1, 2021 (Actual)
Primary Completion Date
October 1, 2022 (Actual)
Study Completion Date
October 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Institut Investigacio Sanitaria Pere Virgili

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
General integrated goal of the coordinated project: To elucidate the role of succinate and other metabolites derived from the intestinal microbiota such as Short Chain Fatty Acids (SCFAs), as energy sensing metabolites in the context of obesity and type 2 diabetes (T2D). Specific objectives of Subproject 1 (SP1): 1a. - To investigate whether intermittent fasting (IF) is better than Continued Daily Caloric Restriction (DCR) in terms of metabolic improvement through the study of: 1) the dynamics of gastrointestinal hormones and energy sensing metabolites, 2) the intestinal microbiome, 3) variability on succinate and SCFAs, MCFAs and Biliary Acid after weight loss; Methodology: clinical study: randomized, cross-over design, study participants (n=15) will consume either lifestyle recommendations for a healthy Mediterranean diet under a continued caloric restriction diet (DCR) or will undertake an intermittent (IF) protocol. Clinical, anthropometrical and functional studies. Metabolomics for gut derived metabolites in plasma. Enteroendocrine gastrointestinal dynamics. Metagenomic analysis.
Detailed Description
To investigate whether IF is better than DCR in terms of metabolic improvement through the study of: the dynamics of gastrointestinal hormones and energy sensing metabolites the intestinal microbiome variability on succinate and SCFAs MCFAs and BA after weight loss Human study protocol: A pilot clinical trial in human study participants will be assayed. Participants for intermittent fasting (IF) will be asked to fast for 24 hours on two days of the week (2/5 protocol). 1A.-Design: Utilizing a randomized, cross-over design, study participants (n=15) will consume either lifestyle recommendations for a healthy Mediterranean diet under a continued daily caloric restriction diet (DCR) or will undertake an intermittent (IF) protocol. Each study period will be 8 weeks - total study period will be 16 weeks + a 4-week washout period between dietary exposures. The study participants will be adults who have obesity with a Body Mass Index (BMI)25 kg/m2 and 40 kg/m2 and have no contraindications for intermittent fasting (see inclusion and exclusion criteria below).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Insulin Sensitivity/Resistance, Diabetes Type 2
Keywords
obesity, diabetes, intermittent fasting, energy-sensing metabolites

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
clinical study: randomized, cross-over design, study participants will consume either lifestyle recommendations for a healthy Mediterranean diet under a continued caloric restriction diet (DCR) or will undertake an intermittent (IF) protocol
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
conventional caloric restriction diet
Arm Type
Other
Arm Description
(DCR protocol): lifestyle recommendations for a healthy Mediterranean diet under a continued daily caloric restriction diet
Arm Title
Intermitent fasting
Arm Type
Other
Arm Description
Fasting for two days (non-consecutive) out of seven, with the fasting days separated by at least one day.
Intervention Type
Other
Intervention Name(s)
dietary intervention
Intervention Description
Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
Primary Outcome Measure Information:
Title
To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of glucose)
Description
Plasma concentrations of glucose during a meal test
Time Frame
basal and after 8 weeks
Title
To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of insulin)
Description
Plasma concentrations of insulin during a meal test
Time Frame
basal and after 8 weeks
Title
To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of glucose after crossing arm)
Description
Plasma concentrations of glucose during a meal test
Time Frame
at beginning of week 12 vs week 20
Title
To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of insulin after crossing arm)
Description
Plasma concentrations of insulin during a meal test
Time Frame
at beginning of week 12 vs week 20
Secondary Outcome Measure Information:
Title
1) the dynamics of gastrointestinal hormones and energy sensing metabolites
Description
GLP-1; GLP-2 during a meal test
Time Frame
8 weeks - 20 weeks
Title
2) Analysis of microbial species in fecal samples (gut flora)
Description
intestinal microbiome after each interventional period
Time Frame
8 weeks - 20 weeks
Title
variability on succinate after weight loss
Description
quantification of succinate
Time Frame
8 weeks - 20 weeks
Title
variability on Short-chain fatty acids (SCFAs) after weight loss
Description
quantification of SCFAs
Time Frame
8 weeks - 20 weeks
Title
variability on Medium-chain fatty acids (MCFAs) after weight loss
Description
quantification of MACFAs
Time Frame
8 weeks - 20 weeks
Title
variability on biliary acids (BA) after weight loss
Description
quantification of BA
Time Frame
8 weeks - 20 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: White men and women between 18 and 65 years of age. BMI range between 25 and 40 kg/m2 Absence of underlying pathology in medical and physical examination, except for those related to excess weight. Signature of the informed consent for participation in the study. Exclusion Criteria: Serious systemic disease not related to obesity, such as cancer, kidney or severe liver disease. Systemic diseases with intrinsic inflammatory activity (autoimmune diseases such as rheumatoid arthritis and asthma) Pregnancy and lactation. Vegetarians or subjects subjected to an irregular diet. Patients with severe eating disorders. Patients with clinical symptoms and signs of infection in the previous month. Patients with chronic anti-inflammatory steroid treatments and/or nonsteroidal anti-inflammatory drugs. Recent antibiotic treatment. Psychiatric history. Uncontrolled alcoholism or drug abuse.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joan J Vendrell, PhD
Organizational Affiliation
Director
Official's Role
Study Director
Facility Information:
Facility Name
Hospital Universitari Joan XXIII de Tarragona. IISPV
City
Tarragona
ZIP/Postal Code
43005
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Data sharing will be upon request directly to the PI

Learn more about this trial

Energy -Sensing Metabolites in Caloric Restriction

We'll reach out to this number within 24 hrs